TG Therapeutics Shares Key Presentation Details for BRIUMVI
![TG Therapeutics Shares Key Presentation Details for BRIUMVI](https://investorshangout.com/images/blog/ihnews-TG%20Therapeutics%20Shares%20Key%20Presentation%20Details%20for%20BRIUMVI.jpg)
Upcoming Data Presentations for BRIUMVI
TG Therapeutics, Inc. (NASDAQ: TGTX) has announced an exciting lineup of data presentations set to occur at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. The focus is on BRIUMVI (ublituximab-xiiy), a treatment aimed at patients suffering from relapsing forms of multiple sclerosis (RMS). This meeting takes place from September 18 to 20 and is set to be a platform for sharing pivotal clinical trial results.
Key Presentation Highlights
Data presented will showcase results from the ULTIMATE I & II Phase 3 trials, as well as insights from the ENHANCE Phase 3b trial. These studies evaluate the effectiveness and tolerability of BRIUMVI, offering clinicians and patients critical information about advancing MS treatments.
The schedule of presentations is outlined below, detailing the focus and timing:
Poster Presentation Details
Title: Five years of Ublituximab in relapsing multiple sclerosis: additional results from open-label extension of ULTIMATE I and II studies
Date/Time: Wednesday, September 18 at 16:15 – 18:15 CEST
Session: Poster Session 1 – Room D3
Abstract Number: Abstract 2102/P324
Lead Author: Dr. Bruce Cree from the Weill Institute for Neurosciences.
Title: Efficacy and tolerability of ublituximab after transitioning from different therapies: Updates from the ENHANCE study
Date/Time: Wednesday, September 18 at 16:15 – 18:15 CEST
Session: Poster Session 1 – Room D3
Abstract Number: Abstract 2259/P329
Lead Author: Dr. John Foley from Rocky Mountain Multiple Sclerosis.
Title: Comparison of Multiple Sclerosis Disease Activity Test results between Ublituximab and Teriflunomide
Date/Time: Wednesday, September 18 at 08:00 CEST
Session: ePoster
Abstract Number: Abstract 1382/eP1516
Lead Author: Dr. John Foley.
Availability of Data
Post-presentation, the presented data will be accessible on TG Therapeutics' website under the Publications section, offering a comprehensive resource for healthcare professionals and interested parties.
Understanding BRIUMVI
BRIUMVI is a unique monoclonal antibody that selectively targets CD20-expressing B-cells, crucial in treating autoimmune diseases, including RMS. Its innovative glycoengineering sets it apart, reducing sugar molecules for effective B-cell depletion at lower doses. This strategy potentially enhances treatment efficacy while minimizing side effects.
Clinical Trials Overview
The ULTIMATE I & II trials enrolled 1,094 patients over 96 weeks, comparing the efficacy of BRIUMVI versus teriflunomide. Key selection criteria included prior relapses and specific disability status, focusing on a population demanding advanced therapeutic solutions.
Additionally, BRIUMVI's safety profile has been under scrutiny. While infusion reactions were reported, monitoring and appropriate premedication have proven effective in reducing severe incidences during clinical trials.
Patient Support Initiatives
TG Therapeutics remains committed to patient care beyond just treatment. The BRIUMVI Patient Support program offers resources tailored to assist patients throughout their treatment journey, ensuring they have access to all necessary support mechanisms during their therapy.
Frequently Asked Questions
What is BRIUMVI?
BRIUMVI is an innovative monoclonal antibody designed to treat relapsing forms of multiple sclerosis by targeting CD20-expressing B-cells.
When will the ECTRIMS meeting occur?
The ECTRIMS annual meeting will be held from September 18 to 20, 2024.
What presentations will TG Therapeutics showcase?
TG Therapeutics will present data from the ULTIMATE I & II trials and the ENHANCE study on efficacy and tolerability of ublituximab.
How can I access the presented data?
The data will be available on the Publications page of the TG Therapeutics website following the presentations.
Where can I find more information about the company?
You can visit TG Therapeutics' official website at www.tgtherapeutics.com for comprehensive company insights and updates on their research and support programs.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Powell Max Limited IPO Raises $5.7 Million with PMAX Shares
- Exploring Roth Contributions for Retirement Planning in Your 50s
- Unlocking Profitable Investment Strategies for Success
- Axoni Achieves Prestigious Award for Operational Risk Excellence
- The Future of Baby Diapers: A Market Set for Expansion
- Eclipse Corporation Launches Testing for Revolutionary DocOrigin Cloud
- Nokia Shines as Leader in 2024 Gartner Magic Quadrant for 5G
- Crafting a Future: The Transforming Beer Market Landscape
- Top U.S. Cities for Young Veterans Seeking Affordable Homes
- Is CrossFirst Bankshares Getting a Fair Deal? An Investigation
Recent Articles
- Seagram's Vodka Partners with USO to Support Military Families
- U.S. Banking Sector Sees Profit Surge Amid Expense Reductions
- Powell Max Limited IPO Raises $5.7 Million with PMAX Shares
- JPMorgan Analyzes Equity and Credit Markets Amid Recession Fears
- Understanding the Impact of Stock Splits on Tech Stocks
- Exploring Roth Contributions for Retirement Planning in Your 50s
- Unlocking Profitable Investment Strategies for Success
- Discovering Environmental Stories in the Rural South
- Services Sector Shows Modest Growth Amid Economic Pressures
- Axoni Achieves Prestigious Award for Operational Risk Excellence
- White Lodging Achieves High Ranking in Guest Satisfaction
- Understanding Insurance Fraud: Charges and Legal Consequences
- Surge in Automotive Telematics Market Fuels Innovation and Growth
- BRG Welcomes Investment Arbitration Expert Michael Seelhof
- The Future of Baby Diapers: A Market Set for Expansion
- Eclipse Corporation Launches Testing for Revolutionary DocOrigin Cloud
- Uphold Launches FDIC-Insured USD Interest Accounts with High APY
- Navigating the Surge in Data Center Demand and Investments
- Govee Launches Groundbreaking Smart Lighting Products at IFA 2024
- Nokia Shines as Leader in 2024 Gartner Magic Quadrant for 5G
- Crafting a Future: The Transforming Beer Market Landscape
- Exploring the Surge: Streaming Analytics Market Growth Ahead
- Investigation into Better Choice Company Inc. by Ademi LLP
- Top U.S. Cities for Young Veterans Seeking Affordable Homes
- Nichad Davis Honored Again as National Black Lawyer's Top 40 Under 40
- Is CrossFirst Bankshares Getting a Fair Deal? An Investigation
- Subaru Achieves Highest Satisfaction Scores in Recent Survey
- Transforming Communication: ZTE and Orange Liberia Unite
- FASTSIGNS Achieves Record Attendance at Annual Sales Summit
- Join Investors and Companies at Benzinga's SmallCap Conference
- Investigation Launched on Fair Price for Frontier Communications
- 3M Xtract Cubitron II Film Disc 775L: A Decade of Innovation
- Ghana's Strategic Move: Restructuring $13 Billion in Bonds
- Citi Analysts Predict Major Margin Gains for Intel
- Utz Brands Adjusts Financial Forecast Amid Market Changes
- Applied Digital's Stock Soars After Major Funding Announcement
- Navigating the Recent US Stock Market Trends and Insights
- Insight into Baltic Horizon Fund's Sustainability Practices
- Baltic Horizon Fund's Commitment to Sustainable Investing
- Powell Max Limited Sets Price for Initial Share Offering
- Colts Enhance Performance with New Matrix Helix Turf Upgrade
- Innovative Eco-Friendly Writing Solutions from Tom's Studio
- Transforming Pediatric Mental Health Care with CBT Scholarships
- Xiao-I Corporation Expects 25% Revenue Growth in 2024
- Celebrating Global Impact: HHRD's Charitable Outreach Initiative
- Lincoln the Lawyer Unveils Debut Album 'Interludes'
- Endeavor 3D Secures ITAR Status to Boost Defense Manufacturing
- Celebrating a Legacy: Mom's Meals Takes a Stand Against Hunger
- ams OSRAM and LEDVANCE Forge a Bright Future Together
- Orange Liberia and ZTE Enhance Rural Connectivity with New Sites